News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Humana and Norton Healthcare’s Pilot ACO Triggered Both Increased Utilization of Clinical Laboratory Tests and Improved Patient Outcomes

Clinical laboratory managers and pathologists will want to develop strategies for adding value under ACO model

One lesson learned from a pilot accountable care organization (ACO) project is that increased utilization of clinical laboratory testing in appropriate circumstances will contribute to improved patient outcomes. Just one year into a pilot ACO partnership, Norton Healthcare and insurer Humana Inc. (NYSE: HUM) have shown quality gains and some modest savings.

This is encouraging news for pathologists and clinical laboratory managers. It shows that, when physicians participating in ACOs more closely follow evidence-based medicine (EBM) guidelines, the increase in lab test utilization can play the expected role in improving diagnosis and guiding therapeutic choices. However, it should be noted that the results disclosed by the Norton/Humana ACO pilot only cover a short period of time. (more…)

Seven Emerging Life Science Clusters in the United States May Provide Business Opportunities for Clinical Pathology Laboratories

Local medical laboratories and pathology groups can often contract to provide certain services to nearby biotechnology firms

Clinical laboratories and pathology groups lucky enough to be located near one of the nation’s recognized “life science clusters” have an opportunity to create useful business relationships with the pharmaceutical firms, biotechnology companies, and medical device businesses that operate within these clusters.

Biotech firms located in these life science clusters often need some of the medical laboratory testing services commonly offered by local clinical laboratories. Relationships developed for these reasons can often open the door for medical laboratories—particularly in academic centers—to play other roles in helping develop new in vitro diagnostic (IVD) technologies for clinical applications. (more…)

FDA Panel Recommends Approval for OraSure’s In-Home Consumer HIV Test, Despite Some Concerns about False Positive Results

Sensitivity and specificity of test kit for over-the-counter sale does not equal that of HIV assays performed in licensed and accredited clinical laboratories

Despite concerns about the potential for false positive results, an in-home rapid HIV test kit designed to be sold to consumers in pharmacies and other retail outlets cleared one more hurdle on the path to winning clearance by the Food and Drug Administration (FDA) to come to market.

On May 15, the 17 voting members of FDA’s Blood Products Advisory Committee (BPAC), concluded that the benefits of the OraQuick in-home HIV test outweigh the potential risks for consumers, according to a story published at cbsnews.com. The FDA advisory panel’s decision came despite earlier reported concerns regarding decreased accuracy of the OTC test when performed by consumers as compared to results from the professional-use version.
(more…)

Pathologists Take Note: IBM’s Watson to Attack Cancer with Help of WellPoint and Cedars-Sinai

Goal of unique collaboration is to give physicians a more accurate way to diagnose and treat many types of cancer

Two noteworthy healthcare organizations will collaborate with IBM (NYSE: IBM) to explore how IBM’s Watson can be used to help physicians deliver improved outcomes to patients. The collaboration involves one major health insurer and a prominent academic medical center in Los Angeles.

WellPoint, Inc. (NYSE: WLP) will interact with oncology experts at the Cedars-Sinai Cancer Institute in Los Angeles to “educate” and program Watson as a physician’s assistant. What makes this particularly interesting for anatomic pathologists is the potential of this project to marry advances in molecular diagnostics with artificial intelligence in ways that allow physicians to diagnose different cancers earlier and with greater accuracy.

In its story about this development, the Los Angeles Times reported that, per IBM, physicians at Cedars-Sinai Medical Center’s Samuel Oschin Comprehensive Cancer Institute will be the first to use the Watson technology.

The institute’s doctors will serve as advisers and lend expertise to help shape the initiative to develop effective ways to use Watson. “Cedars Sinai will provide the guidelines and insights to put into Watson,” stated Manoj Saxena, General Manager of IBM Watson Solutions, in a story published by Forbes Magazine.

Watson is IBM’s computing system that incorporates deep question answering technology that allows it to search quickly through vast amounts of data, then process it and analyze it in a way similar to that of the human brain. The Watson system is capable of processing the equivalent of about 200 million pages of data in about three seconds, Forbes reported.

(more…)

Sony Makes Sizable Investments in Medical Devices and Clinical Pathology Laboratory Testing

Consumer electronics giant wants to create patient-friendly medical devices and diagnostic kits that will be used in point-of-care settings

Sony is laying groundwork for a major expansion into the world of medical devices, with a particular interest in medical laboratory testing and diagnostic test kits. Experts point to Sony’s new strategy as a sign that prospects in diagnostic testing remain incredibly strong.

Citing unnamed sources, the Israeli business daily Globes printed a story reporting that consumer electronics giant Sony Corporation (NYSE:SNE) is actively seeking to invest hundreds of millions of dollars in Israeli medical technologies.

Confluence of Electronics and Medical Devices Heats Up Sector

This is a major strategy change for Sony and company officials state that Sony will rely less on consumer electronics as it shifts its focus to other sectors, particularly medical devices and clinical diagnostics, in an effort to revive earnings. This was reported in a story reported by Business Week.
(more…)

;